Core Viewpoint - The company, Meizhong Jiahe (02453.HK), announced that its subsidiary, Guangzhou Taihe Oncology Hospital, has been approved to enter the "Hong Kong-Macau Medical Device and Drug Access" list, enhancing its capabilities in oncology treatment and expanding its competitive edge in the market [1] Group 1 - The approval was granted by the Guangdong Provincial Health Commission and the Guangdong Provincial Drug Administration, allowing the hospital to import and use urgently needed clinical drugs and advanced medical devices that are already available in Hong Kong and Macau but not yet approved in mainland China [1] - This qualification positions the company as a specialized oncology medical institution with the ability to utilize innovative drugs and devices from Hong Kong and Macau, thereby broadening its business scope and creating a differentiated competitive advantage in the oncology sector [1] - The initiative will facilitate deeper integration with Hong Kong and Macau's medical resources, enhancing clinical treatment levels and research capabilities, while also optimizing cancer treatment plans and aligning with international medical standards [1]